Academic Study Boosts Belief In TIL Therapies, Including Iovance’s Lifileucel
Company Has Begun Rolling Submission
A new academic study presented at ESMO has provided the first Phase III data for tumor-infiltrating lymphocytes as a potential new therapeutic class, while industry leader Iovance looks set to have early-stage data for its TIL accepted by the US FDA.
You may also be interested in...
Iovance To Press Ahead With Melanoma Cell Therapy Filing Despite Doubters
Iovance has seen its share price collapse after releasing data from a second melanoma patient cohort – but is confident its potential first-in-class therapy is approvable.
Novo Nordisk Broke UK Rules By ‘Disparaging’ Rival Eli Lilly
The Danish company has once again broken UK industry rules, this time by looking to get the upper hand on its GLP-1 receptor agonist market rival Eli Lilly.
Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.